Spots Global Cancer Trial Database for Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study

Official Title: Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study

Study ID: NCT04895202

Conditions

Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity

Interventions

Siponimod

Study Description

Brief Summary: This study is a national, prospective, multicenter, non-interventional (observational) study with the aim to describe the impact of Siponimod treatment in a real-world SPMS population in Switzerland who are treated with Siponimod as per Swiss label.

Detailed Description: Primary data will be collected during an observational period of three years of Siponimod treatment. Additionally, medical history of participants will be collected including EDSS, MRI outcomes, relapses and previous medication to allow the estimation of Siponimod treatment effects on an individual basis. It is planned to include an optional blood draw for a later biomarker analysis.